New Russian Trivalent Hepatitis B vaccine (Bubo<sup>®</sup>-Unigep): Phase I Clinical Study Results and Perspectives of Further Investigations Aiming Registration in Russia
Relevance. The absence of a registered vaccine against G145R escape mutant determines the need to develop a drug for the prophylaxis of infectious hepatitis caused by the hepatitis B virus.The aim of the study was to evaluate the safety and reactogenicity of a new hepatitis B recombinant Bubo®-Unige...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Numikom LLC
2020-01-01
|
| Series: | Эпидемиология и вакцинопрофилактика |
| Subjects: | |
| Online Access: | https://www.epidemvac.ru/jour/article/view/864 |